Insights into Wild-Type and Mutant p53 Functions Provided by Genetically Engineered Mice
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Recent whole-exome sequencing studies of numerous human cancers have now conclusively shown that the TP53 tumor-suppressor gene is the most frequently mutated gene in human cancers. Despite extensive studies of the TP53 gene and its encoded protein (p53), our understanding of how TP53 mutations contribute to cancer initiation and progression remain incomplete. Genetically engineered mice with germline or inducible Trp53 somatic mutations have provided important insights into the mechanisms by which different types of p53 mutation influence cancer development. Trp53 germline mutations that alter specific p53 structural domains or posttranslation modification sites have benefitted our understanding of wild-type p53 functions in a whole organism context. Moreover, genetic approaches to reestablish functional wild-type p53 to p53-deficient tissues and tumors have increased our understanding of the therapeutic potential of restoring functional p53 signaling to cancers. This review outlines many of the key insights provided by the various categories of Trp53 mutant mice that have been generated by multiple genetic engineering approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 2×
“P53 activation resulted in regression of both lymphomas and sarcomas, with the major mechanisms of regression being apoptosis in lymphomas and senescence in sarcomas [Ventura et al., 2007].”
BackgroundMethodThe ATM protein kinase: regulating the cellular response to genotoxic stress, and more
Shiloh, Y., & Ziv, Y. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3546 · Cited by 1,649 · cited 1×
“In response to DNA damage, damage-inducible kinases such as ATM and ATR directly phosphorylate p53 at serine 15 (reviewed in Jenkins et al., 2012; Shiloh and Ziv, 2013].”
Backgroundp53 mutant mice that display early ageing-associated phenotypes
Tyner, S. D., Venkatachalam, S., Choi, J., Jones, S., Ghebranious, N., Igelmann, H., Lu, X., Soron, G., Cooper, B., Brayton, C., et al. (2002) · Nature · doi:10.1038/415045a · Cited by 1,459 · cited 2×
“Hypermorphic Trp53 Alleles Besides addition or restoration of wild-type Trp53 to the mouse, genetically engineered mice with hyperactive p53 activity have also been described [Tyner et al., 2002].”
BackgroundSelf-citationMutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308 · cited 4×
“Cataloging of the missense mutations has revealed “hotspot” mutations (e.g., R175H, G245S, R248W, R249S, R273H, and R282W) that more frequently occur than other types of mutations [Soussi, 2011].”
BackgroundInfluentialWhen mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132 · cited 2×
“…that missense mutant versions of p53 display both dominant negative activities (the capacity to inhibit wild-type p53 and p53 family member functions) and gain-of-function activities (the ability to further promote oncogenic phenotypes in the absence of wild-type p53) [Brosh and Rotter, 2009].”
BackgroundGain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome
Lang, G. A., Iwakuma, T., Suh, Y.-A., Liu, G., Rao, V. A., Parant, J. M., Valentin-Vega, Y. A., Terzian, T., Caldwell, L. C., Strong, L. C., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.006 · Cited by 1,069 · cited 2×
“The first two reported germline missense mutations were Trp53 R172H and R172P, both generated by the Lozano laboratory [Liu et al., 2000; Lang et al., 2004; Liu et al., 2004].”
BackgroundMarino, S., Vooijs, M., van der Gulden, H., Jonkers, J., & Berns, A. (2000) · Genes & Development · doi:10.1101/gad.14.8.994 · Cited by 920
Tumor Suppression in the Absence of p53-Mediated Cell-Cycle Arrest, Apoptosis, and Senescence
Li, T., Kon, N., Jiang, L., Tan, M., Ludwig, T., Zhao, Y., Baer, R., & Gu, W. (2012) · Cell · doi:10.1016/j.cell.2012.04.026 · Cited by 912
TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes
Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210302 · Cited by 884 · cited 2×
“mutation observed in some human cancers [Armstrong et al., 1995; Hernandez et al., 2003; Petitjean et al., 2007].”
BackgroundTelomeres and telomerase in cancer
Artandi, S. E., & DePinho, R. A. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp268 · Cited by 823
Modeling the Therapeutic Efficacy of p53 Restoration in Tumors
Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600 · cited 1×
“Tamoxifen treatment of these mice resulted in immediate activation of p53 functions, extensive apoptosis of lymphoma cells, and a significant survival extension [Martins et al., 2006].”
BackgroundModulation of mammalian life span by the short isoform of p53
Maier, B., Gluba, W., Bernier, B., Turner, T., Mohammad, K., Guise, T., Sutherland, A., Thorner, M., & Scrable, H. (2004) · Genes & Development · doi:10.1101/gad.1162404 · Cited by 586 · cited 2×
“A second hypermorphic p53 mouse reported by Scrable and coworkers globally expressed a 44 kD natural-truncated p53 isoform as a transgene and these mice also displayed accelerated aging phenotypes and a shortened median lifespan similar to those observed in the above described p53 model [Maier et al., 2004].”
MethodDistinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression
Brady, C. A., Jiang, D., Mello, S. S., Johnson, T. M., Jarvis, L. A., Kozak, M. M., Broz, D. K., Basak, S., Park, E. J., McLaughlin, M. E., et al. (2011) · Cell · doi:10.1016/j.cell.2011.03.035 · Cited by 533
Telomerase Reverse Transcriptase Delays Aging in Cancer-Resistant Mice
Tomás-Loba, A., Flores, I., Fernández-Marcos, P. J., Cayuela, M. L., Maraver, A., Tejera, A., Borrás, C., Matheu, A., Klatt, P., Flores, J. M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.09.034 · Cited by 484 · cited 1×
“Such results indicated that enhanced normally regulated Trp53 expression could increase lifespan in the appropriate genetic contexts [Matheu et al., 2007; Tomas-Loba et al., 2008].”
BackgroundDelayed ageing through damage protection by the Arf/p53 pathway
Matheu, A., Maraver, A., Klatt, P., Flores, I., Garcia-Cao, I., Borras, C., Flores, J. M., Viña, J., Blasco, M. A., & Serrano, M. (2007) · Nature · doi:10.1038/nature05949 · Cited by 466 · cited 1×
“Such results indicated that enhanced normally regulated Trp53 expression could increase lifespan in the appropriate genetic contexts [Matheu et al., 2007; Tomas-Loba et al., 2008].”
BackgroundThe pathological response to DNA damage does not contribute to p53-mediated tumour suppression
Christophorou, M. A., Ringshausen, I., Finch, A. J., Swigart, L. B., & Evan, G. I. (2006) · Nature · doi:10.1038/nature05077 · Cited by 382
Liu, G., Parant, J. M., Lang, G., Chau, P., Chavez-Reyes, A., El-Naggar, A. K., Multani, A., Chang, S., & Lozano, G. (2004) · Nature Genetics · doi:10.1038/ng1282 · Cited by 325 · cited 3×
“The first two reported germline missense mutations were Trp53 R172H and R172P, both generated by the Lozano laboratory [Liu et al., 2000; Lang et al., 2004; Liu et al., 2004].”
BackgroundEffects of genetic background on tumorigenesis in p53‐deficient mice
Donehower, L. A., Harvey, M., Vogel, H., McArthur, M. J., Montgomery, C. A., Park, S. H., Thompson, T., Ford, R. J., & Bradley, A. (1995) · Molecular Carcinogenesis · doi:10.1002/mc.2940140105 · Cited by 252
Self-citationFeng, L., Lin, T., Uranishi, H., Gu, W., & Xu, Y. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5389-5395.2005 · Cited by 236 · cited 3×
“The first acetylation site mutants were reported in 2005 by two groups, one changing six lysine acetylation sites to arginine and one changing seven lysine sites to arginine so as to render them nonacetylatable [Feng et al., 2005a; Krummel et al., 2005].”
BackgroundToledo, F., Krummel, K. A., Lee, C. J., Liu, C.-W., Rodewald, L.-W., Tang, M., & Wahl, G. M. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.03.014 · Cited by 199 · cited 2×
“The Wahl laboratory generated a germline mutant Trp53 allele that had deleted six prolines in the proline-rich domain (p53 ) [Toledo et al., 2006].”
BackgroundKrummel, K. A., Lee, C. J., Toledo, F., & Wahl, G. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503068102 · Cited by 187 · cited 4×
“Like the Trp53 mice, the Trp53 mice had relatively normal p53 damage-induced stabilization characteristics and normal cell cycle arrest and apoptosis functions [Krummel et al., 2005].”
BackgroundInfluentialCancer and ageing: convergent and divergent mechanisms
Serrano, M., & Blasco, M. A. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2242 · Cited by 182
Phosphorylation of Serine 18 Regulates Distinct p53 Functions in Mice
Sluss, H. K., Armata, H., Gallant, J., & Jones, S. N. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.3.976-984.2004 · Cited by 152 · cited 1×
“The first Trp53 phosphorylation site mutant mouse was produced by the Jones laboratory, converting ATM/ATR target site Ser18 to Ala18 (Ser15 in human p53) [Sluss et al., 2004] (Table 2).”
MethodDefective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23
MacPherson, D., Kim, J., Kim, T., Rhee, B. K., van Oostrom, C. T., DiTullio, R. A., Venere, M., Halazonetis, T. D., Bronson, R., de Vries, A., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600363 · Cited by 124 · cited 2×
“A second key phosphorylation site mutated in mice was Ser23 (Ser20 in humans) [MacPherson et al., 2004].”
BackgroundIncreased Sensitivity to UV Radiation in Mice with a p53 Point Mutation at Ser389
Bruins, W., Zwart, E., Attardi, L. D., Iwakuma, T., Hoogervorst, E. M., Beems, R. B., Miranda, B., van Oostrom, C. T. M., van den Berg, J., van den Aardweg, G. J., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.20.8884-8894.2004 · Cited by 121
Martínez-Cruz, A. B., Santos, M., Lara, M. F., Segrelles, C., Ruiz, S., Moral, M., Lorz, C., García-Escudero, R., & Paramio, J. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3049 · Cited by 65
Cited by
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517
TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade
Leroy, B., Anderson, M., & Soussi, T. (2014) · Human Mutation · doi:10.1002/humu.22552 · Cited by 408
The Roles of MDM2 and MDMX in Cancer
Karni-Schmidt, O., Lokshin, M., & Prives, C. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040349 · Cited by 296
Otmani, K., & Lewalle, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.708765 · Cited by 279
Cancer therapeutic targeting using mutant–p53-specific siRNAs
Ubby, I., Krueger, C., Rosato, R., Qian, W., Chang, J., & Sabapathy, K. (2019) · Oncogene · doi:10.1038/s41388-018-0652-y · Cited by 50
Metadata
- Authors
- Donehower, L. A.
- Venue
- Human Mutation
- Publisher
- Hindawi Limited
- Published
- 2014-02-05
- Volume
- 35
- Issue
- 6
- Pages
- 715-727
- ISSN
- 1059-7794 (ISSN-L)
- OpenAlex
- W2035908735
- Cited by
- 29
- References
- 26
- FWCI
- 2.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.